Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report
Clinical Case Reports · 2026-11 · 14 (11)
DOI: 10.1002/ccr3.73834 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 03.11.2026. Verfasst von Lingfen Zeng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine The Third People's Hospital of Baiyun District Guangzhou Guangdong China. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) may cause rare life‐threatening ICI‐associated diabetes mellitus. We report a 60‐year‐old Chinese male with pre‐existing type 2 diabetes who developed toripalimab‐induced diabetic ketoacidosis after 3 treatment cycles. He also had toripalimab‐related hyperthyroidism. Clinicians should closely monitor plasma glucose during and after ICI therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine The Third People's Hospital of Baiyun District Guangzhou Guangdong China.
- Department of Clinical Laboratory The Third People's Hospital of Baiyun District Guangzhou Guangdong China.
ORCID-Profile: Lingfen Zeng
Zitieren
APA
Zeng, L., & Sun, J. (2026). Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report. Clinical Case Reports, 14(11). https://doi.org/10.1002/ccr3.73834
Vancouver
Zeng L, Sun J. Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report. Clinical Case Reports. 2026;14(11). doi:10.1002/ccr3.73834
BibTeX
@article{Zeng2026,
author = {Zeng, Lingfen and Sun, Jieming},
title = {Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report},
journal = {Clinical Case Reports},
year = {2026},
volume = {14},
number = {11},
doi = {10.1002/ccr3.73834}
}
EUVIMED